MX2023006832A - Anticuerpos que se unen a receptores de linfocitos t gamma-delta. - Google Patents
Anticuerpos que se unen a receptores de linfocitos t gamma-delta.Info
- Publication number
- MX2023006832A MX2023006832A MX2023006832A MX2023006832A MX2023006832A MX 2023006832 A MX2023006832 A MX 2023006832A MX 2023006832 A MX2023006832 A MX 2023006832A MX 2023006832 A MX2023006832 A MX 2023006832A MX 2023006832 A MX2023006832 A MX 2023006832A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- delta
- cell receptors
- bind gamma
- gamma
- Prior art date
Links
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 title 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a anticuerpos capaces de unirse a un receptor de linfocitos T V?9V?2 humano. La invención se refiere además a composiciones farmacéuticas que comprenden los anticuerpos de la invención y a los usos de los anticuerpos de la invención para el tratamiento médico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20213166 | 2020-12-10 | ||
PCT/EP2021/085079 WO2022122973A1 (en) | 2020-12-10 | 2021-12-09 | Antibodies that bind gamma-delta t cell receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023006832A true MX2023006832A (es) | 2023-08-22 |
Family
ID=73793117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023006832A MX2023006832A (es) | 2020-12-10 | 2021-12-09 | Anticuerpos que se unen a receptores de linfocitos t gamma-delta. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230303694A1 (es) |
EP (1) | EP4259660A1 (es) |
JP (1) | JP2024501403A (es) |
KR (1) | KR20230157933A (es) |
CN (1) | CN116888153A (es) |
AU (1) | AU2021395439A1 (es) |
CA (1) | CA3200826A1 (es) |
IL (1) | IL303045A (es) |
MX (1) | MX2023006832A (es) |
WO (1) | WO2022122973A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
EP4292610A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
ES2537207T3 (es) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Métodos para la generación de anticuerpos multiespecíficos y multivalentes |
ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
CA2892193C (en) | 2012-11-21 | 2018-06-19 | Pharmabcine Inc. | Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same |
JP6617138B2 (ja) * | 2014-04-10 | 2019-12-11 | ラヴァ・セラピューティクス・ベー・フェー | ヒトVγ9Vδ2 T細胞受容体と結合する免疫グロブリン |
US20210371525A1 (en) | 2018-09-19 | 2021-12-02 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
WO2020159368A1 (en) * | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
-
2021
- 2021-12-09 CA CA3200826A patent/CA3200826A1/en active Pending
- 2021-12-09 JP JP2023532452A patent/JP2024501403A/ja active Pending
- 2021-12-09 WO PCT/EP2021/085079 patent/WO2022122973A1/en active Application Filing
- 2021-12-09 IL IL303045A patent/IL303045A/en unknown
- 2021-12-09 EP EP21824387.1A patent/EP4259660A1/en active Pending
- 2021-12-09 CN CN202180090574.0A patent/CN116888153A/zh active Pending
- 2021-12-09 MX MX2023006832A patent/MX2023006832A/es unknown
- 2021-12-09 AU AU2021395439A patent/AU2021395439A1/en active Pending
- 2021-12-09 KR KR1020237023004A patent/KR20230157933A/ko unknown
-
2023
- 2023-06-09 US US18/332,165 patent/US20230303694A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230303694A1 (en) | 2023-09-28 |
KR20230157933A (ko) | 2023-11-17 |
CN116888153A (zh) | 2023-10-13 |
WO2022122973A1 (en) | 2022-06-16 |
IL303045A (en) | 2023-07-01 |
EP4259660A1 (en) | 2023-10-18 |
CA3200826A1 (en) | 2022-06-16 |
AU2021395439A1 (en) | 2023-06-22 |
JP2024501403A (ja) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000448A (es) | Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta. | |
MX2021009285A (es) | Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40). | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
PH12017502358A1 (en) | Factor xi antibodies and methods of use | |
MX2023006832A (es) | Anticuerpos que se unen a receptores de linfocitos t gamma-delta. | |
MX2019009358A (es) | Anticuerpo anti-gprc5d y molecula que comprende el anticuerpo. | |
EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
MX2019007347A (es) | Anticuerpo anti-cd3 y moleculas que comprenden el anticuerpo. | |
MY156702A (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies | |
PH12019502763A1 (en) | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
MX349198B (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
MX2023001491A (es) | Moleculas de union a gp130 y metodos de uso. | |
EA201390813A1 (ru) | Антитела и их применение | |
MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
EA202193309A1 (ru) | Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы | |
MX2021005085A (es) | Formulacion de anticuerpo. | |
MY170404A (en) | Antigen binding proteins | |
MX2021001524A (es) | Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso. | |
MX2023009950A (es) | Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta. | |
MX2023005346A (es) | Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8. | |
MX2022007855A (es) | Anticuerpos hvem anti-humano (tnfrsf14) y usos de los mismos. | |
EA201390117A1 (ru) | Композиция антител к vegfr-3 | |
SG11202107538VA (en) | Formulations of antibodies that bind human cd137 and uses thereof |